CRISPR Therapeutics AG (CRSP): Capital Expenditures
$914.0K
Year ended 2025-12-31
$1.74M
Trailing 12 months to 2026-06-30
-70.9%
3-year compound annual growth
-45.1%
5-year compound annual growth
-2.3%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $914.0K | -51.9% | 2026-02-12, From 2025-01-01 |
| 2024-12-31 | $1.90M | -79.9% | 2026-02-12, From 2024-01-01 |
| 2023-12-31 | $9.47M | -74.5% | 2026-02-12, From 2023-01-01 |
| 2022-12-31 | $37.19M | -54.5% | 2025-02-11, From 2022-01-01 |
| 2021-12-31 | $81.70M | +345.1% | 2024-02-21, From 2021-01-01 |
| 2020-12-31 | $18.36M | +174.7% | 2023-02-21, From 2020-01-01 |
| 2019-12-31 | $6.68M | +141.0% | 2022-02-15, From 2019-01-01 |
| 2018-12-31 | $2.77M | -64.5% | 2021-02-16, From 2018-01-01 |
| 2017-12-31 | $7.81M | +159.1% | 2020-02-12, From 2017-01-01 |
| 2016-12-31 | $3.02M | +161.4% | 2019-02-25, From 2016-01-01 |
| 2015-12-31 | $1.15M | n/a | 2018-03-08, From 2015-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $914.0K | -51.9% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $128.0K | +392.3% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $134.0K | -42.7% |
| Ocugen, Inc. (OCGN) | 2025-12-31 | $185.0K | -94.5% |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $4.53M | -37.9% |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | $23.0K | n/a |
| Aligos Therapeutics, Inc. (ALGS) | 2024-12-31 | $130.0K | +584.2% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $532.0K | -77.2% |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $884.0K | -43.8% |
Compare CRSP, SRZN, CGON, OCGN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗